A Phase I/II Study of MG1 Maraba/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients With Incurable Advanced/Metastatic MAGE-A3-Expressing Solid Tumours
This research is being done because these viruses have been shown to shrink tumours in
animals and human tumour samples by selectively killing cancer cells and creating an immune
response to the tumour antigen contained in the viruses. This effect has been shown to
increase when the AdMA3 virus is given first. It is not clear if this treatment will offer
better results than standard treatment.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society